←
Alexander Staruschenko2,457 posts
Alexander Staruschenko avatar

Alexander Staruschenko

@staruschenko

Professor @USFHealthMed. Director of @USF_HKRC. Studying renal ion channels and their role in the control of BP and CKD.

◷ Joined September 2019▧ 573 Photos and videos
오창명 avatar
⟳ Alexander Staruschenko retweeted
오창명@changmyung1981·Oct 13

🧬🫘 What if mitochondrial dysfunction in diabetic kidney disease is not one disease mechanism—but several distinct, cell-specific processes requiring different treatments? A new Perspectives in Diabetes article in Diabetes proposes a framework for understanding mitochondrial dysfunction across renal compartments and disease stages. The central concept: The same mitochondrial response may be protective in one kidney cell type but harmful in another. 🔬 1. Mitochondrial dysfunction evolves with disease progression The authors describe three overlapping stages: Early DKD: Hyperfiltration, increased tubular transport, oxygen demand, and compensatory mitochondrial responses. Intermediate DKD: Lipotoxicity, mitochondrial ROS accumulation, impaired fatty acid oxidation (FAO), and defective mitophagy. Advanced DKD: mtDNA-dependent inflammation, cellular injury, fibrosis, and nephron loss. Importantly, these processes do not occur uniformly across renal compartments. ⚡ 2. Proximal tubules: From metabolic overload to mitophagy failure Proximal tubular cells depend heavily on mitochondrial oxidative metabolism. Diabetes increases SGLT2-dependent sodium–glucose reabsorption, raising ATP and oxygen requirements. Progressive lipid accumulation activates: KIM-1-mediated lipid uptake → CD36-associated FAO impairment → mtROS ↑ → NLRP3 activation Meanwhile, CERS6-derived ceramides inhibit PINK1/Parkin-dependent mitophagy. Protective pathways include: HIF-1α/HO-1 | DsbA-L | PACS-2 | PINK1 | YAP1 These pathways preserve mitochondrial dynamics, organelle contacts, and quality control. 🧬 3. Podocytes: Mitochondria function as stress-signaling organelles Unlike proximal tubules, podocytes rely substantially on glycolysis under basal conditions. Under diabetic stress, mitochondrial dynamics become critical. ROCK1–DRP1 phosphorylation → Excessive mitochondrial fission → mtROS ↑ → Podocyte injury Experimental DRP1 inhibition reduces mitochondrial fragmentation and albuminuria. Additional mechanisms include: • ABCA1 deficiency → Cardiolipin accumulation → Respiratory dysfunction • CERS6 → Ceramide accumulation → mtDNA leakage → cGAS–STING activation • TUG1–PGC-1α → Mitochondrial biogenesis and protection • NDUFS4 → Cristae and respiratory supercomplex stabilization These pathways represent potential compartment-specific therapeutic targets. 🔥 4. Endothelial and immune cells reveal additional mechanisms Glomerular endothelial mitochondria primarily regulate redox signaling and barrier integrity. Mitochondrial oxidative stress → Endothelial dysfunction → Podocyte injury In macrophages, mitochondrial metabolism shapes inflammatory phenotypes. Succinate accumulation → HIF-1α stabilization → IL-1β production Interestingly, TREM2-high macrophages may protect against metabolic kidney injury. Mitochondrial dysfunction can therefore either amplify inflammation or support tissue repair, depending on cellular context. 💊 5. Toward precision mitochondrial therapeutics Established DKD treatments—including SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists—may indirectly reduce mitochondrial stress. Emerging experimental strategies include: • Restoring mitophagy and mitochondrial quality control • Modulating mitochondrial fission and redox signaling • Targeting ceramide and cardiolipin metabolism • Improving NAD⁺ homeostasis • Inhibiting mtDNA–cGAS–STING inflammatory signaling However, indiscriminate mitochondrial activation may be counterproductive. 💡 The broader implication The next generation of DKD research should integrate single-cell and spatial omics, mitochondrial functional assays, metabolic flux analysis, and cell-specific genetic perturbations. The therapeutic question is no longer simply how to improve mitochondrial function. It is which mitochondrial pathway to target, in which renal cell population, and at which stage of diabetic kidney disease. 📄 Shapiro A, Tiwari R, Staruschenko A. Mitochondrial Dysfunction Across Renal Compartments in Diabetic Kidney Disease. Diabetes. 2026. Perspectives in Diabetes. DOI: doi.org/10.2337/dbi26-0024 #DiabeticKidneyDisease #DKD #Mitochondria #Mitophagy #SGLT2 #Podocytes #Metabolism #NLRP3 #cGASSTING #KidneyResearch #PrecisionMedicine #DrugDiscovery

Post attachment
Eunji Paige Chung avatar
⟳ Alexander Staruschenko retweeted
Eunji Paige Chung@TheChungLab·Oct 19

Our lab is accepting Postdoc and research technician applicants - those that are committed to collaborative research and supporting therapeutic development are encouraged to apply!

Our lab, in conjunction with the Transformative Center for Nanomedicine, has openings for postdocs and research technicians. Email eunchung@usc.edu with CV and interests, and for more information.

Post attachment
USF Hypertension and Kidney Research Center avatar
⟳ Alexander Staruschenko retweeted
USF Hypertension and Kidney Research Center@USF_HKRC·Oct 15

Great example of how nephrology and rheumatology can work together to improve patient care! Great to see @USFHealth and @TGHCares bringing these specialties together to provide coordinated, multidisciplinary care for patients with lupus nephritis. #Nephrology #Rheumatology #Lupus

For patients with lupus nephritis, navigating care can mean coordinating multiple specialists, appointments and treatment plans, making an already complex disease even more difficult to manage. USF Health is changing that! Launched in 2025, the Comprehensive Lupus Nephritis Clinic brings rheumatology and nephrology together to provide same-day, multidisciplinary care, helping patients receive coordinated care, support early detection and move quickly from diagnosis to treatment. The clinic is a joint effort between USF Health and Tampa General Hospital, bringing together expertise and resources to support patients throughout their care. Read more about this innovative approach to lupus nephritis care at the link in bio: usf.edu/health/news/2026/usf…

1:39
Alexander Staruschenko avatar
Alexander Staruschenko@staruschenko·Oct 8

Thank you so much for the kind words and congratulations! I am truly honored to receive the Donald Seldin Lectureship Award from @KidneyInCVD @AHA_Research. Grateful to my colleagues, collaborators, and trainees who have contributed to this recognition. #Hypertension2026

Post attachmentPost attachment

Excited about the @KidneyInCVD highest achievement award: the Donald Seldin lecture, awarded this year to @staruschenko. So well deserved! Congratulations! 👏🏽👏🏽👏🏽🎉🎉 @hyoersouthforida #hypertension2026

Post attachmentPost attachment
Sen. Susan Collins avatar
⟳ Alexander Staruschenko retweeted
Sen. Susan Collins@SenatorCollins·Sep 21

The Office of Management and Budget (OMB) should not be involved in agency decisions on the awards of grants. As I stated in my July 6 letter, a proposed OMB rule would politicize grantmaking. The Continuing Resolution—which passed the Senate, House, and was signed into law on September 2—blocks OMB’s proposed rule or any substantially similar one. Any attempt to politicize grantmaking at the National Institutes of Health (NIH), or any other agency, by another means—whether an Executive Order or guidance—is contrary to congressional intent. Imposing a political review on awards that have already been selected through a rigorous scientific and merit-based process undermines the long-standing principle that the government funds awards based on scientific need and merit, rather than political ideology.